Spinal Cord Compression: An Infrequent Complication of SAPHO Syndrome

Rekik, S.; Slouma, M.; Sahli, H.; Chéour, E.; Elleuch, M.

doi:10.5606/archrheumatol.2015.5571

Cited by 3 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 4 TNFis have been increasingly used in clinical practice, 4,45 mainly infliximab 9 followed by etanercept, 46 adalimumab, 47 and certolizumab pegol. 48 Several reports have proven the effectiveness of these agents on both cutaneous and osteoarticular involvement.…”

Section: Tnf Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological Management of Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome Syndrome

Slouma

Bettaieb²,

Rahmouni³

et al. 2021

J Clin Rheumatol

View full text Add to dashboard Cite

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare chronic disease with marked clinical and radiological heterogeneity. It is characterized by a combination of dermatological and osteoarticular manifestations. The treatment of SAPHO syndrome is not yet codified. It includes several therapeutic options such as anti-inflammatory drugs, bisphosphonates, antibiotics, conventional disease-modifying antirheumatic drugs, and biological treatment.This article aims to provide an updated review of the different pharmacological options for SAPHO syndrome. We also propose a therapeutic algorithm for the management of this disease.

show abstract

Section: Tnf Inhibitorsmentioning

confidence: 99%

“…Overall, 4 TNFis have been increasingly used in clinical practice, 4,45 mainly infliximab 9 followed by etanercept, 46 adalimumab, 47 and certolizumab pegol 48 …”

Section: Pharmacological Optionsmentioning

confidence: 99%

Pharmacological Management of Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome Syndrome

Slouma

Bettaieb²,

Rahmouni³

et al. 2021

J Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…[3] Notably, SAPHO syndromes rarely cause spinal deformity, and only rare cases require reconstructive surgery. [1,5,6,8,10] Here, a 62-year-old female with SAPHO syndrome and destructive C5-C7 spondylodiscitis warranted circumferential decompression/fusion.…”

Section: Introductionmentioning

confidence: 99%

“…Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, a noninfectious inflammatory disease, can rarely cause destructive spondylodiscitis. [8] Following sternocostoclavicular lesions (65~90%), the spine is the 2 nd most commonly affected region (32~52%). [3] Notably, SAPHO syndromes rarely cause spinal deformity, and only rare cases require reconstructive surgery.…”

Section: Introductionmentioning

confidence: 99%

Destructive spondylodiscitis associated with SAPHO syndrome: A case report and literature review

Takeuchi¹,

Hanakita²,

Takahashi³

et al. 2022

Surgical Neurology International

View full text Add to dashboard Cite

Background: Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare sterile inflammatory disease characterized by cutaneous and osteoarticular lesions. Associated spinal lesions chronically manifest slight or no neurological symptoms. Only rarely does destructive spondylodiscitis occur. Case Description: A 62-year-old female with palmoplantar pustulosis presented with a rapidly progressive quadriparesis. When the cervical MR showed destructive spondylodiscitis at the C5–C7 level, the patient underwent anterior debridement followed by posterior reconstruction/fixation. The histopathology showed a nonspecific inflammatory process with vertebral sclerosis consistent with the diagnosis of SAPHO; cultures were negative. Postoperatively, the patient’s symptoms improved and SAPHO did not recur. Conclusion: Destructive spondylodiscitis associated with SAPHO syndrome is uncommon. Early diagnosis and surgical treatment result in the best outcomes.

show abstract